RxDoctor Payments DataLook up a doctor →

Baran Kilical, MD

Cardiovascular Disease · Annapolis, MDNPI 1891835385

Payments from drug & device makers

$30,817in general payments, 2019–2025

Across 309 payments — averaging $99.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$21K
  • Medtronic$7K
  • Edwards Lifesciences$329
  • Boston Scientific$317
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$257
  • E.r. Squibb & Sons, L.L.C.$219
  • plus $2K from 37 others

What the payments were for

  • Consulting fees$10,55034%
  • Speaking & faculty fees$7,01823%
  • Travel & lodging$4,22814%
  • Food & beverage$9,02129%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$30,817 in reported general payments places this provider in the 85th percentile of 507 cardiovascular disease providers in Maryland.

See all cardiovascular disease providers in Maryland

Medicare billing

Part B allowed, 2024
$500,531
Medicare patients
646
Services billed
3,297

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban219$299,849
XareltoRivaroxaban41$56,456
Repatha SureclickEvolocumab30$22,262
Repatha SyringeEvolocumab16$8,375
Rosuvastatin Calcium160$4,563
Metoprolol Succinate194$3,966
Ezetimibe27$2,032
Flecainide Acetate20$1,455
Nifedipine ErNifedipine27$1,315
Losartan Potassium76$969
Amiodarone Hcl41$870
Atorvastatin Calcium90$706
Diltiazem 24hr Er (Cd)Diltiazem Hcl28$678
Chlorthalidone13$383
Amlodipine Besylate58$361

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$172$299,849219 claims
Johnson & JohnsonXarelto$31$56,45641 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 507 cardiovascular disease providers in Maryland.

Other cardiovascular disease in Annapolis

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →